Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71.
Vogelzang
Nicholas J
NJ
Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA. nvogelzang@nvcancer.org